Related Experiment Video
Updated: Jul 12, 2025
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
Empirical Study on Exploring the Role of CD180 and MD-1 Prognostic Indicators for the Chronic Lymphocytic Leukaemia
Insights
CD180 and MD-1 expression showed no significant difference in Chronic Lymphocytic Leukaemia (CLL) patients. However, they were significantly different in subgroups based on Rai staging, FISH, and IgVH mutational status, indicating prognostic value.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Chronic Lymphocytic Leukaemia (CLL) is a prevalent hematologic malignancy.
- Understanding prognostic indicators is crucial for managing CLL.
- CD180 and MD-1 are investigated for their role in CLL pathogenesis, involving cell signaling and proliferation.
Purpose of the Study:
- To investigate the prognostic role of CD180 and MD-1 in Chronic Lymphocytic Leukaemia (CLL).
- To compare CD180 and MD-1 expression with established CLL biomarkers.
Main Methods:
- Quantitative analysis of CD180 and MD-1 expression in 52 CLL patients and 12 controls.
- Comparison with Immunoglobulin Heavy Chain variable region gene (IgVH) mutational status, fluorescence in situ hybridization (FISH), and Rai staging.
Main Results:
- CD180 and MD-1 protein expression showed no significant differences among CLL patients overall.
- Significant differences in CD180 and MD-1 expression were observed in subgroups defined by Rai staging, FISH (13q deletion), and IgVH mutational status.
Conclusions:
- CD180 and MD-1 may serve as prognostic indicators in CLL.
- These markers correlate with established prognostic factors, potentially impacting cell cycle and survival outcomes in CLL.
Abstract:
<b>Background and Objective:</b> Chronic Lymphocytic Leukaemia (CLL) is a frequent type of leukaemia disease. This study was focused on investigating the role of prognostic indicators, such as CD180 and MD-1 for Chronic Lymphocytic Leukaemia (CLL) pathogenesis because they involve cell signalling and proliferation. <b>Materials and Methods:</b> A total of 12 normal controls and 52 patients were taken to determine the expressions of CD180 and MD-1 with different variations in comparison with the IgVH (Immunoglobulin Heavy Chain variable region gene) mutational status, FISH (fluorescence <i>in situ</i> hybridization) and Rai staging. <b>Results:</b> The quantitative data findings were evident that CD180 and MD-1 expressions showed insignificant differences among CLL patients at the protein level based on SPSS results. On the contrary, they resulted in significant differences for subgroups of established biomarkers like Rai staging (stages 0, I, II and III), FISH (13q and non-13q deletions) and IgVH (mutated and unmutated). <b>Conclusion:</b> The CD180 and MD-1 have been used as prognostic indicators to evaluate the outcomes relevant to the cell cycle and survival rate of CLL cells.
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
10:18From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014